Elanco Animal Health heads into the first week of June with a striking contradiction: short sellers have rebuilt positions aggressively while the company's own CEO put fresh money to work at the lows.
Short interest has surged this past month and the speed of the move is the standout feature. SI jumped 25% in a single week — from roughly 5.1% to 6.4% of free float — with the bulk of that jump arriving on May 26, when shares outstanding on loan leaped from 25.6 million to 31.5 million almost overnight. Over a rolling month the position has grown 33%, and at 6.4% of free float the short book is now comfortably above the level that warrants attention. The ORTEX short score has climbed accordingly, from 49.6 at the start of last week to 54.0 — not extreme, but trending in a clear direction. Days to cover stand at 3.9 on official FINRA data, which means any covering event would take nearly four sessions to unwind.
The lending market, however, doesn't look like a setup for a squeeze. Availability is generous at 338%, meaning there are more than three shares available to borrow for every share currently borrowed — well within the normal range and barely changed on the week. Cost to borrow is a low 0.52%, down 5% on the week despite the spike in short interest. Shorts are piling in, but the borrow market is accommodating them easily. Options sentiment tells a similar story of mild caution rather than alarm: the put/call ratio is 0.61, actually leaning below its 20-day mean of 0.67, suggesting call activity has been relatively firm even as short sellers rebuild. The z-score of -1.07 puts options positioning at a standard-deviation below recent averages — more bullish than bearish in the options market, at least for now.
The Street reads the stock constructively. JP Morgan raised its target to $30 following the May earnings print, maintaining Overweight. Citigroup lifted to $31 at the same time. The consensus target sits near $29.79 against a current price of $23.63, implying roughly 26% potential return — a gap that has encouraged a broadly positive analyst skew. The bull case rests on Simparica Trio holding above 50% market share in companion animal parasiticides, Credelio Quattro ascending toward a 16-plus percent market share, and forward EPS momentum that ranks in the 77th percentile of the ORTEX universe. EV/EBITDA at 15.1x has compressed slightly over the past month. The bear case centres on refinancing risk: with leverage still elevated and interest rates not particularly friendly, refinancing headwinds could weigh on 2026 earnings growth — and the EV/EBIT factor score of 13 reflects how poorly the stock screens on that dimension.
The most pointed counterpoint to the short-interest rebuild is what management did with its own money. On May 15, CEO Jeff Simmons bought roughly $100,000 worth of shares at $20.09. EVP Rajeev Modi bought a near-identical amount the same day. These are modest in absolute dollar terms but carry signal weight: both executives had sold shares at $24.88 in early March, and came back in below $21. The stock has since recovered to $23.63, up 4.1% on the month and 3.5% on the week. Institutional holders remain anchored, with Dodge & Cox at 13.8% and BlackRock and Fidelity each near 9.5%.
Earnings aren't scheduled until August 6, so the next test for positioning is not imminent. What matters between now and then is whether the short rebuild represents a considered view on the refinancing and margin story — or is a momentum-driven addition now sitting uncomfortable above a stock that has already clawed back most of May's selloff. The divergence between the aggressive short rebuild and the firm options tone, alongside the CEO's on-record purchase at lower prices, is the tension worth tracking heading into Q3.
See the live data behind this article on ORTEX.
Open ELAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
